Benzimidazole-based fXa inhibitors with improved thrombin and trypsin selectivity

Area of Science:

• Medicinal Chemistry
• Biochemistry
• Pharmacology

Background:

• Factor Xa (fXa) inhibitors are critical in anticoagulation therapy.
• Achieving selectivity against related proteases like thrombin and trypsin is essential for minimizing side effects.
• Benzimidazole-based scaffolds are explored for their potential in developing novel anticoagulants.

Purpose of the Study:

• To optimize benzimidazole-based compounds for enhanced selectivity towards Factor Xa (fXa).
• To investigate the impact of specific chemical modifications on inhibitor potency and selectivity profiles.
• To improve selectivity against thrombin and trypsin, key serine proteases in the coagulation cascade.

Main Methods:

• Systematic substitution on the benzimidazole ring of inhibitor compounds.
• Replacement of the naphthylamidine moiety with alternative amidine groups.
• Assays to evaluate inhibitor potency against fXa and selectivity against thrombin and trypsin.

Main Results:

• Substitution with a nitro group at the 4-position of the benzimidazole significantly improved fXa potency and thrombin selectivity.
• Replacing the naphthylamidine group with biphenylamidine or propenylbenzamidine enhanced fXa potency and selectivity against both thrombin and trypsin.
• These modifications demonstrate a clear structure-activity relationship for optimizing fXa inhibitors.

Conclusions:

• Chemical modifications of benzimidazole-based compounds can effectively enhance selectivity for Factor Xa (fXa).
• Strategic substitutions and group replacements are viable approaches to develop potent and selective anticoagulants.
• The optimized inhibitors show promise for improved therapeutic applications in anticoagulation.